Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
Despite mixed fan and critic reactions to the final season of "Game of Thrones," the eight-season epic took home the top prize in the drama category at the Emmy Awards on...Entertainmentread more
There are alternative financial centers and investors can turn to Singapore, Tokyo or Shanghai if Hong Kong doesn't "shape up," says the founder and chairman of Citic Capital.Asia Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
U.S. President Donald Trump's national security advisor said on Sunday that White House Asia policy adviser Matt Pottinger would become his top deputy.Politicsread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
But if the market pays little attention to natural disasters, situations like North Korea's failed missile launch do tend to rattle whole swaths of stocks, Cramer said.
"I think that this news coming out of North Korea ... would certainly produce a much higher price for this stock" on Tuesday, Cramer said of Kratos Defense, a government defense contractor. "Now, the missile is in the water, but it doesn't matter. I think that there'll be another spurt in all of the defense stocks, and Kratos will figure prominently in that."
Six Flags' stock may have gotten hit after a weaker-than-expected earnings report in July, but CEO Jim Reid-Anderson told CNBC that he has since only reaffirmed his faith in the company.
"Last Friday, I spent $3 million buying the company's shares because I believe that the stock price, where it is today, doesn't reflect the true value of this company," Reid-Anderson told Cramer on Monday. "A 5.1 percent yield, Jim. That's the highest yield in the industry. And so right now, it's an opportunity."
While the CEO acknowledged that management was disappointed with the earnings miss, he maintained that revenue and profitability reached record highs in the second quarter.
He also said that in six of the last seven years, Six Flags shares declined during the third-quarter period, making this quarter the prime time to buy the stock.
"No two horrendous storms are alike. They're all terrible, and while it continues, the only thing that matters is that people are dying. Anything else is just much, much less important," the "Mad Money" host said. "But I know that many of you want to know if Harvey has any impact on investing, specifically on your portfolios, so I've got some ideas based on history."
So Cramer put together a worst-case scenario for those invested in the storm based on the havoc wreaked by Hurricane Katrina, another Category 3 storm that killed 2,000 and caused $100 billion in damage, according to the Federal Emergency Management Agency.
Then, Cramer spoke with Veeva Systems founder and CEO Peter Gassner, who spoke to the cloud company's new QualityOne product.
The cloud-based quality management program applies to new fields for Veeva that include cosmetics, chemicals, food and industrial manufacturing, Gassner said.
"We have an offering for them now, and we're just starting to get traction out there," the CEO told Cramer on Monday. "We're talking about health and human safety, absolutely, but we're also talking about quality as it refers to the brand reputation."
Gassner said the biggest draw for new QualityOne customers was their need to coordinate quality management with suppliers. The best way to reach suppliers is through a cloud-based system, and no programs exist currently that serve that kind of correspondence, Gassner said.
"We're going to serve this under-served market," Gassner said. "It reminds me of what ServiceNow did when they really started focusing on IT operations, really bringing a cloud solution ... and all of a sudden you've got a big market. That's what we're trying to do with QualityOne. There's a big, pent-up demand there, and I think we're uncovering it."
Finally, Cramer looked into Esperion Therapeutics, a small-capitalization, development-stage biotechnology company that just issued a large secondary offering.
"When a little company with a red-hot stock does a big equity offering, that tends to be a pretty strong signal that you need to get more cautious," Cramer warned.
Amid years of wild trading, Esperion, which focuses on treatments for high cholesterol, has issued several stock offerings, usually following promising news about its drugs.
"First, you have to remember, as an early-stage biotech with no drugs on the market, no earnings, and no sales, this stock trades purely on how people feel about its longer-term prospects," Cramer explained. "The bottom line is that early-stage biotech stories are inherently risky. The last time Esperion did a secondary offering after announcing strong data, its stock ended up losing 90 percent of its value before it bottomed. I'm not saying that'll happen again. I just think you need to be careful, and while the company has definitely improved and it's farther along and we love stage 3, stocks like Esperion? Well, I've learned my lesson. I think they're too risky for me to recommend on Mad Money."
In response to CNBC's request for comment, an Esperion spokesperson emphasized the company's announcement of positive top-line results in its Phase 2 study of a treatment for inflammation associated with cardiovascular disease.
"Based on the positive reaction to this news, the company made the decision to opportunistically conduct a financing, helping to further strengthen their financial position as they progress further in to Phase 3 development and approval. As importantly, the financing provided large, long-term, institutional investors the opportunity to build substantial ownership positions in Esperion," the spokesperson wrote. "It's also important to highlight that the management team of Esperion continues to be "fully-invested" in the current and future success of the bempedoic acid franchise. We are large and long-term holders of Esperion stock and options."
In Cramer's lightning round, he flew through his take on some callers' favorite stocks:
KBR Inc.: "OK, that's a construction company. Could be an interesting play off of what's happening in Houston, but I am going to say let's hold off because it has too much energy exposure."
Corcept Therapeutics: "Oh man, the stock's up 100 percent. But, you know, look, they have the possibility of something for psychiatric disorders, therefore I'm going to tell you that I think that the company's a good spec. Because I know that there's a lot of buzz about what this company's up to."